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ORIGINAL ARTICLE

Percutaneous Coronary Interventions in Chronic
Total Occlusion e Proﬁle, Technique and Outcome
eThe Malabar Experience
Desabandhu Vinayakumar, Madhusudan Pramod Raikar*,
Kurukkanparampil Sreedharan Mohanan
Department of Cardiology, Government Medical College, Kozhikode, Kerala 673008, India

Abstract
Introduction: Percutaneous coronary intervention (PCI) of chronic total occlusion (CTO) remains a challenge. The
reasons being that these procedures may be lengthy and complex, with elevated radiation exposure, increased contrast
load, lower procedural success rate, and a higher risk of complication when compared with non-CTO elective PCI.
Clarifying the long-term clinical outcomes of CTO-PCI is very important to justify potential investments in training
and technology. However, there is a paucity of data from Indian subcontinent. Hence we decided to report the outcomes
from a real-life cohort of consecutive patients undergoing elective PCI for CTO at our institution.
Materials and methods: Single-center, prospective observational study. A total of 339 consecutive patients who underwent elective PCI for chronic total occlusion between Feb 2016 to Feb 2018 were included in the study. Procedural
techniques, complications and clinical outcomes {all-cause death, cardiac death, major adverse cardiac events (MACE)
and target vessel revascularization (TVR)} were assessed in our study population.
Results: 339 patients were prospectively followed up for a duration that ranged from 3 months to 36 months, with a
median follow up of 24 months. Overall procedural success was achieved in 85.5% (n ¼ 290) cases. No signiﬁcant differences were noted in In-Hospital adverse events (5.5% vs. 4.1%; p 0.998). MACE rate was signiﬁcantly higher in unsuccessful CTO group (36.7% vs. 8.9%, p 0.001) and was predominantly driven by Ischemia Driven (ID) Revascularization (16.3% vs. 3.1%, p < 0.001). Cardiac death and All-cause death was not signiﬁcantly different between
the groups. Residual angina (26.5% vs. 10%, p 0.003) and residual dyspnoea (34.7% vs. 12.4%, p < 0.001) were signiﬁcantly worse in unsuccessful CTO group.
Conclusions: Procedural success in the present drug-eluting stent (DES) era is more than 80% and newer techniques and
hardwares have improved the procedural success rate, especially in younger age groups. MACE rates were signiﬁcantly higher
in the unsuccessful CTO group. Residual angina and dyspnoea were signiﬁcantly worse in the unsuccessful CTO group.
Keywords: CTO-PCI, Successful CTO-PCI, Microcatheter, MACE, ID-Revascularization

1. Introduction

P

ercutaneous coronary intervention (PCI) has
improved outcomes dramatically in coronary
artery disease (CAD) management. But despite
being commonly encountered in patients undergoing coronary angiography, percutaneous treatment of chronic total occlusion (CTO) remains a

challenge [1,2]. Recanalization of a CTO is
attempted in only 10%e15% of patients undergoing percutaneous coronary intervention (PCI)
[3]. The reasons being that the CTO PCI procedures may be lengthy and complex, with elevated
radiation exposure, increased contrast load, lower
procedural success rate, and a higher risk of
complication when compared with non-CTO
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elective PCI [4,5]. One other reason is the uncertainty of the prognostic impact of percutaneous
CTO revascularization.
Patients with a chronically occluded single-vessel
disease (SVD) are often managed medically regardless
of the severity of symptoms and extent of ischemia, as
the anatomy is deemed to be stable. Whereas, those
with multivessel disease (MVD) involving a CTO may
be referred for coronary artery bypass graft (CABG)
surgery even if other lesions are suitable for PCI [1,6].
Some studies indicate that successful CTO PCI may
improve left ventricular function and survival when
compared with failed CTO PCI [7e9]. But some studies
do not show the beneﬁt [10,11]. Clarifying the longterm clinical outcomes of CTO-PCI is very important to
justify potential investments in training and technology, and the potential risks involved. Recently there
have been a few studies in DES era which have shown
long term beneﬁts on clinical outcomes. However,
there is a paucity of data from Indian subcontinent.
Hence we decided to report the outcomes from a reallife cohort of consecutive patients undergoing elective
PCI for CTO at our institution. This is the ﬁrst CTO PCI
study from northern Kerala traditionally called as
Malabar region, after the provincial name of erst while
British madras presidency.
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Abbreviations used:
CTO
PCI
MACE
TVR
ID
DES
sCTO
uCTO
ACS
UA
NSTEMI
STEMI
CABG
CIN
LVEF
HTN
DM
DLP
CKD
PAD
SVD
DVD
TVD
LM
EA
AWMI
IWMI
LWMI
DAPT

chronic total occlusion
percutaneous coronary interventions
major adverse cardiac events
target vessel revascularization
ischemia driven
drug eluting stent
successful chronic total occlusion intervention
unsuccessful chronic total occlusion intervention
acute coronary syndrome
unstable angina
non ST elevation myocardial infarction
ST elevation myocardial infarction
coronary artery bypass grafting
contrast induced nephropathy
left ventricular ejection fraction
hypertension
diabetes mellitus
dyslipidemia
chronic kidney disease
peripheral artery disease
single vessel disease
double vessel disease
triple vessel disease
left main
effort angina
anterior wall myocardial infarction
inferior wall myocardial infarction
lateral wall myocardial infarction
dual anti platelet therapy

2. Materials and Methods
2.1. Study design
A prospective observational study.
2.2. Study setting
Single centre e department of cardiology, Medical
College Hospital (MCH), Kozhikode, Kerala, India.
2.3. Study population
A total of 339 consecutive patients who underwent
elective PCI for chronic total occlusion between
February 2016 to February 2018 were included in the
study.
2.4. Inclusion criteria
1. Patients undergoing elective PCI for CTOs in Dept. of cardiology, MCH, Kozhikode.
2. Age 18 years and willing to give written informed consent

2.5. Exclusion criteria
1. Patients with an estimated duration of total occlusion less
than 3 months

2. Patients with contraindications for dual antiplatelet therapy
(DAPT)
3. Patients with second or third failed attempt of CTO-PCI
4. Patients with end-stage renal disease (ESRD) with eGFR less
than 15 ml/kg/m2
5. Patients with incomplete data entry
6. Patients not willing for the study

2.6. End points
1.
2.
3.
4.

All cause death
Cardiac death
Target vessel revascularization (TVR)
MACE (composite of non-fatal MI, cardiac death, stroke and
need for TVR)

2.7. Follow up
Patients were followed up during the outpatient
department (OPD) visits or by a telephonic interview with a minimum follow up of 3 months.
2.8. Statistical analysis
Categorical variables were analyzed using the
Pearsons chi-square test when appropriate (expected frequency >5). Otherwise, the Fisher's exact
test was used.
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Continuous variables were expressed as mean
with standard deviation and compared using the
independent student t-test.
Time was measured from the ﬁrst admission for a
procedure to an outcome (all-cause mortality).
Signiﬁcance was inferred at p-value < 0.05.
All the statistical analysis were made using SPSS
software (version 10.2, IBM).
2.9. Ethical clearance
The study was approved by the institutional
ethical committee (IEC) at government medical
college, Kozhikode.

3. Methodology
All the procedures were performed by a single
operator.
All patients were pre-treated with aspirin (325 mg)
and clopidogrel (300e600 mg).
Only drug-eluting stents were deployed.
The use of Gp IIb/IIIa inhibitors was at the
discretion of the operator.
Preference of access site, approach to CTO-PCI,
use of microcatheter/penetration catheter/cutting
balloon and other special techniques was at the
discretion of the operator.
After the procedure, all the patients were maintained on DAPT for as long as possible with a
minimum of 6 months.
Patient outcomes were stratiﬁed according to
successful (sCTO) or unsuccessful (uCTO) CTO
recanalization.

Patients undergoing an initial unsuccessful procedure but undergoing a subsequent successful
attempt were classiﬁed as successful.
Data were prospectively entered into a clinical
database at the time of the PCI by the performing
physician.
Following data was collected:
Patient Characteristics: age, sex, previous acute
coronary syndrome (ACS)/PCI/coronary artery
bypass grafting (CABG), hypertension, diabetes
mellitus, dyslipidemia, peripheral vascular disease,
new york heart association (NYHA) functional class,
smoking status, chronic renal failure [eGFR between
15 and 90 ml/kg/m2or on renal replacement therapy], left ventricular function.
Procedure-Related Data: access site, target vessel,
number of diseased vessels, approach to CTO-PCI,
ﬂouro time, heparin dose, contrast volume and
number of stents deployed.
Procedural Complication Data: access site complications, no/slow ﬂow, side branch occlusion, need
for emergency CABG, the incidence of CIN.
Clinical Outcome Data: MACE, cardiac death, allcause death, need for TVR, residual angina/
dyspnoea.

4. Results
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Table 1. Baseline Characteristics
BASELINE CHARACTERISTICS

sCTO
n ¼ 290 (%)

uCTO
n ¼ 49 (%)

TOTAL n ¼ 339 (%)

P-value

AGE (mean þ S.D.)
Male SEX, n (%)
HTN, n (%)
DM, n (%)
DLP, n (%)
SMOKING, n (%)
CKD, n (%)
OBESITY, n (%)
PAD, n (%)
EA III/IV, n (%)
Previous MI, n (%)
AWMI
IWMI
LWMI
Previous ACS, n (%)
UA
NSTEMI
STEMI
Previous PCI, n (%)
Previous CABG, n (%)
LVEF < 50, n (%)

57.45 ± 9.09
246 (84.8)
161 (55.5)
144 (49.7)
60 (20.7)
78 (26.9)
18 (6.2)
34 (11.7)
11 (3.8)
102 (35.2)
93 (32.1)
50 (17.2)
42 (14.5)
01 (0.34)
129 (44.5)
4 (1.4)
32 (11.0)
93 (32.1)
6 (5.5)
1 (0.9)
44 (15.2)

57.95 ± 7.57
48 (97.9)
21 (42.8)
24 (48.9)
9 (18.4)
16 (32.7)
4 (8.2)
5 (10.2)
4 (8.2)
24 (48.9)
19 (38.8)
06 (12.2)
13 (26.5)
0
20 (40.8)
0
1 (2.0)
19 (38.8)
0
0
3 (6.1)

57.35 ± 9.17
294 (86.7)
182 (53.7)
168 (49.5)
69 (20.3)
31 (9.1)
22 (6.5)
39 (11.5)
15 (4.4)
126 (37.2)
112 (33.0)
56 (16.5)
55 (16.2)
01 (0.29)
149 (43.9)
4 (1.2)
33 (9.7)
112 (33.0)
6 (4.7)
1 (0.8)
47 (13.9)

0.716
0.01
0.121
0.998
0.848
0.087
0.539
0.998
0.247
0.078
0.411
0.532
0.056
e
0.755
e
0.064
0.411
e
e
0.116

4.1. Demographics
A total of 339 patients were followed up for a
duration that ranged from a minimum of 3 months
to a maximum of 36 months. The median follow-up
was 24 months in our study population.
The baseline characteristics of both groups were
comparable. The baseline characteristics of our
study population are shown in Table 1.
The mean age of our study population was
57.35 ± 9.17 overall. The mean age in sCTO group
was 57.45 ± 9.09 and it was 57.95 ± 7.57 in the uCTO
group. There was no signiﬁcant difference between
the mean age in both these groups.
However, when we compared different age
groups, unsuccessful CTO-PCI was more common
in the elderly age group as shown in Table 2 And
Fig. 1.
We had more number of males overall in our
study group 86.7% (n ¼ 294) compared to females
13.3% (n ¼ 45). Male sex was 84.8% (n ¼ 290) and
97.9% (n ¼ 49) in sCTO and uCTO groups respectively. Though it was statistically signiﬁcant in
uCTO group, it was skewed data since we had very
less female patients in our study group.

Both groups were comparable with respect to
other baseline demographics.
Patients having effort angina class III-IV were
numerically more in uCTO group, but were not
statistically signiﬁcant.
Most of the patients included in our study were
having a good baseline LV ejection function. Patients with LV dysfunction (EF < 50%) were
numerically more in sCTO group but was not statistically signiﬁcant.
4.2. Procedural data
Overall successful CTO-PCI was achieved in
85.5% (n ¼ 290) and unsuccessful CTO-PCI was
seen in 14.5% (n ¼ 49). Table 3 shows the procedural
data of our study population.

Table 2. Age Wise Distribution Of Procedural Success.
<50
50 - 59
60 - 69
70

SUCCESS

FAILURE

TOTAL

52 (91.2)
106 (85.5)
113 (84.3)
19 (79.1)

05
18
21
05

57
124
134
24

(8.8)
(14.5)
(15.7)
(21.9)

Fig. 1. Age Wise Distribution Of Procedural Success.
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Table 3. Procedural Data 1.
Procedural Data:
ACCESS SITE, n (%)
Femoral
Dual Femoral
APPROACH
Antegrade
Retrograde
VESSELS INVOLVED
SVD
DVD
TVD
LM þ SVD
LM þ DVD
LM þ TVD
CTO VESSEL
LAD
LCX
RCA
DIAGONAL
OM
PDA/PLV
LAD þ LCX
LAD þ RCA
LCX þ RCA
MICROCATHETER USE
Fine cross
Corsair
Crusade
Caravel
CUTTING BALLOON USE
ANCHORING BALLOON USE
BALLOON EMBEDDING IN SIDE BRANCH

sCTO
n ¼ 290 (%)

uCTO
n ¼ 49 (%)

TOTAL n ¼ 339 (%)

84 (28.9)
206 (71.1)

12 (24.5)
37 (75.5)

96 (28.3)
243 (71.7)

277 (95.5)
13 (4.5)

47 (95.9)
2 (4.1)

324 (95.6)
15 (4.4)

145 (50.0)
98 (33.8)
44 (13.8)
1 (0.3)
1 (0.3)
2 (0.7)

24 (49.0)
16 (32.7)
8 (16.3)
0
0
1 (2.0)

169 (49.9)
114 (33.6)
52 (15.3)
1 (0.3)
1 (0.3)
3 (0.9)

0.99
0.870
0.831
e
e
0.373

125 (43.1)
24 (8.3)
117 (40.3)
2 (0.7)
3 (1.0)
3 (1.0)
5 (0.9)
7 (1.8)
6 (1.8)

15 (30.6)
7 (14.3)
24 (49.0)
0
0
0
0
0
3 (6.1)

140 (41.3)
31 (9.1)
141 (41.6)
2 (0.6)
3 (0.9)
3 (0.9)
5 (1.5)
7 (2.0)
9 (2.6)

0.117
0.182
0.275
e
e
e
e
e
0.126

170 (58.6)
8 (2.8)
2 (0.7)
17 (5.8)
2 (0.7)
10 (3.4)
13 (4.5)

30 (61.2)
3 (6.1)
1 (2.0)
4 (8.2)
0

200 (58.9)
11 (3.2)
3 (0.9)
21 (6.2)
2 (0.6)
10 (2.9)
13 (3.8)

0.756
0.202
0.373
0.522
e
e
e

All the study patients underwent viability testing
with cardiac magnetic resonance (CMR) imaging,
and only patients with signiﬁcant viable myocardium were included in the study.
All the patients underwent PCI through the
femoral route. The majority of the cases needed a
dual femoral access. However, there was no statistically signiﬁcant difference in the outcome based
on the access used.
Most of the CTO-PCI was performed through the
anterograde approach. Only a few were performed
through a retrograde approach. Anterograde loose
tissue tracking (ALTT) with serial wire escalation
was the most common technique used. Anterograde
sub-intimal tracking and reentry (ASTR) was used
in a few cases. For a retrograde approach, subintimal tissue tracking was employed. However,
there was no statistically signiﬁcant difference in
relation to the outcome.
Since the serial wire escalation strategy was used,
only a few (17%) lesions could be crossed with intermediate wires, and most (83%) lesions required
stiff wires.

0

P-value
0.608
0.998

J-CTO score was calculated to assess the
complexity of lesions in all our patients. Mean JCTO score was 2.05 ± 1.22 in sCTO group &
2.63 ± 1.56 in uCTO group. uCTO group had a
higher proportion of patients with worse scores, as
depicted in Fig. 2.
In our study, the success rate was higher in the left
anterior descending artery (LAD) territory followed
by the right coronary artery (RCA) territory. It was
lowest in the left circumﬂex artery (LCX) territory,
as shown in Fig. 3. However, the outcomes were not
signiﬁcantly related.
Though procedural success was higher in LAD
territory, there were no signiﬁcant differences in
outcome. Fig. 4 shows the success rate in LAD in
comparison to other territories.
Special hardware like microcatheter, penetration
catheter and cutting balloons were used in most of
the cases at operator's discretion. In the remaining
cases, only monorail balloon were used. Fig. 5 shows
the different hardware used in our study population. However, their use was not statistically
signiﬁcant.
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Fig. 2. J-CTO score.

Fluoroscopy time, heparin dose and contrast volume used in our population are tabulated in Table 4.
No statistically signiﬁcant difference was noted between our study groups.
4.3. Complications
Access site complications were the most common
procedure-related complications overall. It was
signiﬁcantly more common in uCTO group (8.3% vs.
20.4%; p 0.017). Predominantly driven by TIMI
major and minor bleeds.
Other complications like perforation, side branch
occlusion, no ﬂow/slow ﬂow, cardiac tamponade,
cardiac arrest, contrast-induced nephropathy and
need for emergency CABG were seen in only a
minority of patients and was not signiﬁcantly
related to the outcome. Table 5 lists the complications encountered in our study groups.

Fig. 3. Procedural success in various arterial territory.

4.4. Clinical outcomes
Our study population had very few in-hospital
adverse events, predominantly driven by MACE as
depicted in Table 6. However, they were not statistically signiﬁcant.
All cause death and cardiac death were marginally
higher in uCTO group but were not statistically
signiﬁcant as shown in Table 7.
New onset ACS was signiﬁcantly higher in uCTO
group (5.5% vs. 14%; p 0.033) which was predominantly driven by non ST-elevation ACS (NSTEACS).
ST-elevation myocardial ischemia (STEMI) rates,
however were not signiﬁcantly related to outcomes.
MACE was signiﬁcantly higher in uCTO group
(36.7% vs. 8.9%, p 0.001) and was predominantly
driven by Ischemia Driven Revascularization (16.3%
vs. 3.1%, p < 0.001).
The need for CABG was signiﬁcantly higher in
uCTO group (16.3% vs. 0.7%, p < 0.001) and was the
predominant means of revascularization in uCTO
group.

Fig. 4. Procedural success in LAD vs non LAD territory.
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Fig. 5. Hardwares use in our study.

Table 4. Procedural Data 2.
Flouro Time (min)
Heparin Dose (ml)
Contrast Volume (ml)

Group

N

Mean

S.D.

sCTO
uCTO
sCTO
uCTO
sCTO
uCTO

290
49
290
49
290
49

25.99
27.06
7935.78
7631.58
218.99
218.68

12.64
12.27
952.82
573.53
88.07
90.93

Residual angina (26.5% vs. 10%, p 0.003) and residual dyspnoea (34.7% vs. 12.4%, p < 0.001) were
signiﬁcantly worser in uCTO group.
DAPT was continued beyond 12 months in most
of our patients. Only a few patients had discontinued them before 12 months. However, that
was not signiﬁcantly related to the outcomes. Details
of the duration of dual antiplatelet therapy is as
depicted in Table 8.

5. Discussion
Our study was a single centre, single operator
experience in real life in south Indian population.
We had procedural success in 85.5% of patients. A
meta-analysis by Patel et al. [13] of 65 studies with
18,061 patients and 18,941 target CTO vessels

showed angiographic success in 77%. Few recent
studies with the use of modern techniques have
shown a procedural success of more than 80%
[14,15]. Our results were consistent with these
recent studies.
The mean age of our patients was 56.96 ± 9.17. It
was observed that procedural success declined as
the age advanced (91.2% in <50yrs vs. 79.1% in
>70yrs).
We had large male population (86.7%), similar to
the extensive UK registry database (78.8% males of
13,443 CTO patients) [16].
Some of the previous studies [17,18] included
more patients with older age, lower left ventricular
ejection fraction, and previous MI in uCTO group,
whereas we did not have any such discrepancy.
Patients with a previous history of revascularization did not have a worse outcome, unlike in previous studies [18].
Patients with worse J-CTO score had poorer outcomes as found in previous studies [15].
We observed that the success rate was 90.3% in
LAD territory, whereas it was 81.2% in LCX territory
and 84.3% in RCA territory.
Previous studies [19] have reported a signiﬁcant
beneﬁt in survival after successful PCI of a CTO
located in the LAD territory but not after successful
PCI of a CTO located in the circumﬂex or right
coronary arteries. However, in our study, though
procedural success was higher in LAD territory,
there was no signiﬁcant differences in outcome.
Use of special hardwares like micro catheter,
penetration catheter and cutting balloon was done
in most of the cases and hence led to higher procedural success. However, they were not signiﬁcantly different among our study groups.
We also noted that ﬂuoroscopy time, heparin dose
and contrast volume were marginally higher in
uCTO group but was not signiﬁcant.

Table 5. Complications.
Complications

sCTO
n ¼ 290

uCTO
n ¼ 49

TOTAL n ¼ 339

P-Value

ACCESS SITE COMPLICATIONS, n (%)
TIMI Minor Bleed
TIMI Major Bleed
Peudoaneurysm
Perforation, n (%)
Minor
Major
Side Branch Occlusion, n (%)
No Flow/Slow Flow, n (%)
Tamponade, n (%)
Cardiac Arrest, n (%)
Emergency CABG
CIN, n (%)

24 (8.3)
16 (5.5)
5 (1.7)
3 (1.0)
6 (2.0)
4 (1.3)
2 (0.7)
4 (1.3)
5 (1.7)
2 (0.7)
1 (0.3)
1 (0.3)
9 (3.1)

10 (20.4)
6 (12.3)
3 (6.1)
1 (2.0)
3 (6.1)
2 (4.1)
1 (2.0)
0
0
1 (2.0)
0
0
2 (4.1)

34 (10.0)
22 (6.4)
8 (2.4)
4 (1.2)
9 (2.7)
6 (1.8)
3 (0.9)
4 (1.2)
5 (1.5)
3 (0.6)
1 (0.3)
1 (0.3)
11 (3.3)

0.017
0.108
0.093
0.466
0.126
0.209
0.373
e
e
0.373
e
e
0.663

Table 6. In-Hospital Adverse Events.
IneHospital
Adverse Events

sCTO
n ¼ 290

uCTO
n ¼ 49

TOTAL n ¼ 339

P-Value

Cardiac Death, n (%)
MACE, n (%)
STEMI, n (%)
Target vessel Re-PCI, n (%)

0
16 (5.5)
1 (0.3)
1 (0.3)

0
2 (4.1)
0
0 (0)

0
18 (5.3)
1 (0.3)
1 (0.3)

e
0.998
e
e

Table 7. Long term clinical outcomes.
Outcomes

sCTO
n ¼ 290

uCTO
n ¼ 49

TOTAL n ¼ 339

P-Value

All Cause Death, n (%)
Cardiac Death, n (%)
MACE, n (%)
NEW ACS, n (%)
UA
NSTEMI
STEMI
STEMI, n (%)
ID-Target Vessel
Revascularization, n (%)
Re - PCI, n (%)
CABG, n (%)
Residual Angina, n (%)
Residual Dyspnoea, n (%)

9 (3.1)
6 (2.1)
26 (8.9)
16 (5.5)
5 (1.7)
9 (3.1)
2 (0.7)
2 (0.7)
9 (3.1)

3 (6.1)
2 (4.1)
13 (36.7)
7 (14.3)
2 (4.1)
4 (8.2)
1 (2.0)
1 (2.0)
8 (16.3)

12 (3.5)
8 (2.4)
39 (11.5)
23 (6.8)
7 (2.1)
13 (3.8)
3 (0.9)
3 (0.9)
17 (5.0)

0.391
0.333
0.001
0.033
0.267
0.102
0.373
0.373
<0.001

7 (2.4) ‘
2 (0.7)
29 (10.0)
36 (12.4)

0
8 (16.3)
13 (26.5)
17 (34.7)

7 (2.1)
10 (2.9)
42 (12.4)
53 (15.6)

e
<0.001
0.003
<0.001

Previous studies had postulated that the complications of CTO-PCI might have some inﬂuence on
the mortality after PCI.
Japanese CTO registry showed a coronary perforation rate of 7.2% [15]. Mehran et al. [12] reported
the rate of coronary perforation and residual
dissection rate of 7.4% and 9.4%, respectively in an
unsuccessful CTO group.
In our study, we had a perforation rate of 6.1% in
uCTO group though it was not statistically signiﬁcantly related to outcomes.
Access site complications were the most common
complication encountered (20.4 vs. 8.3%; p 0.017)
and was predominantly driven by TIMI major and
minor bleeds.
Severe complications such as cardiac tamponade,
cardiac arrest or need for emergency CABG were
not signiﬁcantly different in our study groups. In
contrast, they were more frequent in the failed PCI
group in previous studies.

Olivari et al. [8] reported that 2.3% of patients in
the failed CTO-PCI group underwent emergent
CABG, but we had none in our study.
Suero et al. [20] reported that the incidence of inhospital major adverse cardiac events was signiﬁcantly high in the failed CTO-PCI group but our
study did not show any such difference.
Successful CTO-PCI was not associated with a
lesser risk for all-cause death and cardiac death over
a follow up of 3 yrs unlike previous studies [12].
Probable reasons being, ﬁrstly, Subsequent coronary revascularization in uCTO group might have
attenuated the possible long-term mortality beneﬁt
of successful CTO-PCI. Secondly, the difference in
the background characteristics of patients. Because
of the relatively high initial success rate, the successful CTO-PCI group included many patients
with complex clinical and procedural characteristics,
who are deemed to have a poor long-term prognosis. We can postulate that many complex patients

Table 8. Duration Of Dual Antiplatelet Therapy.
DURATION OF DAPT

Total

LESS THAN 6 MONTHS
6 - 12 MONTHS
MORE THAN 12
MONTHS

sCTO

uCTO

Total

P - value

2
9
279

0
1
48

2
10
329

e
0.998
0.998

290

49

339
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included in the sCTO group in our study could be
included in the uCTO group in previous studies.
Thirdly, a lesser number of procedural complications in uCTO group could have had better long
term results.
MACE rate was signiﬁcantly higher in uCTO
group compared to sCTO group (36.7% vs. 8.9%, p
0.001) and was predominantly driven by Ischemia
Driven Revascularization (16.3% vs. 3.1%, p < 0.001).
Valenti et al. [17] reported that the incidence of
CABG at one year was 9.1% in the failed PCI group.
Need for CABG in the uCTO group over a period of
3 yrs 16.3% and was the predominant mode of
revascularization in uCTO group.
Successful CTO-PCI had signiﬁcantly low residual
angina(26.5% vs. 10%, p 0.003) and residual dyspnoea (34.7% vs. 12.4%, p < 0.001).
Most of the patients continued DAPT for more
than 12 months. Except for 2 patients who had to
discontinue it within 6 months owing to non-cardiac
surgery and 10 patients discontinued between 6 and
12 months (6 due to excessive bleeding and 4 defaulters). However, it was not signiﬁcantly related to
outcomes.
There is no randomized controlled trial
comparing PCI plus medical therapy with medical
therapy alone in patients with CTO. Prospective
randomized trials comparing PCI plus medical
therapy with medical therapy alone in patients with
CTO, adequately powered for evaluating long-term
mortality, are absolutely required to deﬁne the
indication of CTO-PCI.
5.1. Study limitations
Our study was an observational study. Prospective
randomized control trials are required to compare
PCI plus medical therapy with medical therapy
alone to deﬁne indications for CTO-PCI. We had a
variable duration of follow up, though the median
follow up was 24 months. A longer duration of
follow up might show better results. Our study was
underpowered to evaluate mortality beneﬁts in a
successful CTO group. We did not have any
angiographic follow up. We did not include a non
CTO-PCI comparison group. Hence, we do not
know how the outcomes of CTO-PCI group compares with the other non CTO-PCI groups. Unsuccessful CTO group used as a surrogate for medical
therapy. A proper comparison with medical therapy
alone will be more useful clinically.

6. Conclusions
1. Procedural success in the present drug-eluting stent era is
more than 80%, and newer techniques and hardwares have
improved the procedural success rates.
2. Successful CTO-PCI was not associated with a lesser risk for
all-cause death and cardiac death over a follow up of up to
3 yrs.
3. MACE rates were signiﬁcantly higher in the unsuccessful
CTO-PCI group.
4. Ischemia Driven-Revascularization rates were signiﬁcantly
higher in patients with unsuccessful CTO-PCI.
5. The need for subsequent CABG was very high in the unsuccessful CTO-PCI group.
6. Residual angina and residual dyspnoea were signiﬁcantly
worse in the unsuccessful CTO-PCI group.
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